| Drug ID: | Drug29 |
|---|---|
| Drug Name: | Midazolam |
| CID: | 4192 |
| DrugBank ID: | DB00683 |
| Modality: | Small Molecule |
| Groups: | approved|illicit |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02760615, , NCT03358706 |
| Molecular Formula: | C18H13ClFN3 |
| Molecular Weight: | 325.8 g/mol |
| Isomeric SMILES: | CC1=NC=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4F |
| Synonyms: | midazolam; 59467-70-8; Buccolam; Midazolamum; 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine; mezolam; Midazolamum [INN-Latin]; Nayzilam; Midazolam civ; USL261 |
| Phase 0: | 22 |
| Phase 1: | 454 |
| Phase 2: | 132 |
| Phase 3: | 109 |
| Phase 4: | 279 |
| Description: | A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. [PubChem] Midazolam is a schedule IV drug in the United States. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt268 | 4192 | Midazolam | 7124 | TNF | Mus musculus (house mouse) | 37330271 | NFIL3 protein affects the reaction [jujuboside A affects the reaction [[midazolam co-treated with lipopolysaccharides] affects the expression of TNF protein]]|jujuboside A affects the reaction [[midazolam co-treated with lipopolysaccharides] affects the e |
| dt269 | 4192 | Midazolam | 54209 | TREM2 | Mus musculus (house mouse) | 37330271 | [midazolam co-treated with lipopolysaccharides] affects the expression of TREM2 mrna|jujuboside A affects the reaction [[midazolam co-treated with lipopolysaccharides] affects the expression of TREM2 mrna]|nfil3 protein affects the reaction [jujuboside A |
| dt270 | 4192 | Midazolam | 7200 | TRH | Rattus norvegicus (Norway rat) | 2845442 | Midazolam inhibits the reaction [TRH protein modified form binds to TRHR protein] |
| dt271 | 4192 | Midazolam | 7201 | TRHR | Rattus norvegicus (Norway rat) | 2845442 | Midazolam inhibits the reaction [TRH protein modified form binds to TRHR protein] |
| dt272 | 4192 | Midazolam | 706 | TSPO | Mus musculus (house mouse) | 19857560 | Midazolam results in increased expression of TSPO protein |
| dt273 | 4192 | Midazolam | 706 | TSPO | Rattus norvegicus (Norway rat) | 33823148 | [ketamine co-treated with midazolam co-treated with valproic acid] inhibits the reaction [[sarin co-treated with [atropine co-treated with trimethylene-bis(4-hydroxyiminomethylpyridinium)]] results in increased expression of TSPO protein] |
| dt274 | 4192 | Midazolam | 706 | TSPO | Rattus norvegicus (Norway rat) | 7603229 | Midazolam binds to TSPO protein |
| dt275 | 4192 | Midazolam | 7305 | TYROBP | Mus musculus (house mouse) | 37330271 | NFIL3 protein affects the reaction [jujuboside A affects the reaction [[midazolam co-treated with lipopolysaccharides] affects the expression of TYROBP mrna]]|jujuboside A affects the reaction [[midazolam co-treated with lipopolysaccharides] affects the e |
| dt276 | 4192 | Midazolam | 1577 | CYP3A5 | Homo sapiens (human) | CYP3A5 protein affects the metabolism of midazolam | |
| dt277 | 4192 | Midazolam | 1577 | CYP3A5 | Homo sapiens (human) | CYP3A5 protein results in increased hydroxylation of midazolam |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT07161297 | Remimazolam for Colonoscopy in IBD Patients | PHASE4 | NOT_YET_RECRUITING | Humanitas Clinical and Research Center | IBD (Inflammatory Bowel Disease) | DRUG: Intravenous remimazolam (5 mg initially, wi… | Details |
| NCT03358706 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | PHASE1 | TERMINATED | Janssen Research & Development, LLC | Crohn Disease|Ulcerative Colitis | DRUG: Ustekinumab IV Infusion|DRUG: Ustekinumab S… | Details |
| NCT02760615 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | PHASE4 | WITHDRAWN | Takeda | Colitis, Ulcerative|Crohn Disease | DRUG: Caffeine|DRUG: Losartan|DRUG: Omeprazole|DR… | Details |
| NCT01934088 | Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy | PHASE4 | COMPLETED | Copenhagen University Hospital at Herlev | Inflammatory Bowel Disease|Endoscopy|Sedation | DRUG: Propofol|DRUG: Midazolam|DRUG: Fentanyl | Details |
| NCT01489943 | A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | PHASE1 | COMPLETED | GlaxoSmithKline | Crohn's Disease | DRUG: GSK1605786 500 mg|DRUG: Midazolam 3 mg|DRUG… | Details |
| JPRN-jRCTs031200018 | Randomized controlled trial examining the usefulness and safety of midazolam continuous intravenous infusion and pethidine hydrochloride in small intestine endoscope - NHOG-MDZ-GFCF | NULL | Not Recruiting | Sakakibara Yuko | OGIB, Small bowel stenosis, small bowel tumor, in… | Midazolam single intravenous + pethidine hydrochl… | Details |
| EUCTR2013-002428-17-DK | Nurse Administered Propofol Sedation vs combined sedation with midazolam/fentanil for colonoscopy in patients with IBD. A randomised controlled trial of satisfaction and adhearence to treatment program. - Propofol vs. standard sedation for colonoscopy. A | NULL | Not Recruiting | Gastroenheden D, Herlev Hospital | Satisfaction with sedation during colonoscopy in … | Trade Name: Propofol B. BraunProduct Name: Propof… | Details |
| NL-OMON55161 | A PHASE I, RANDOMIZED, DOUBLE BLINDED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE ASCENDING DOSES OF ORAL GDC-8264 AND THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF GDC-8264 IN HEALTHY VOLUN | NULL | Not Recruiting | Genentech, Inc. | Inflammatory Bowel Disease irritable bowel syndro… | The subjects will receive a single or multiple do… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Efficacy and safety analysis of midazolam combined with dezocine sedation and a…
PMID: 37492093
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Objective: Colonoscopy plays an important role in the diagnosis, prognosis prediction, assessment of disease activity and severity, and treatment of …